financetom
Business
financetom
/
Business
/
TransAct Technologies' Q2 sales beat expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TransAct Technologies' Q2 sales beat expectations
Aug 6, 2025 2:49 PM

Overview

* TransAct Q2 net sales rise 19% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q2 beats estimates, reflecting improved profitability

* Co acquires perpetual license for BOHA! software source code

Outlook

* Company expects full-year 2025 net sales between $49 mln and $53 mln

* TransAct forecasts adjusted EBITDA for 2025 to be $0 to $1.5 mln

Result Drivers

* CASINO AND GAMING SALES - Casino and gaming sales increased 42% yr/yr and 14% sequentially, contributing to revenue growth

* FST REVENUE - FST recurring revenue rose 7% yr/yr, reflecting progress in sales strategies

* SOURCE CODE ACQUISITION - Acquisition of BOHA! software source code expected to enhance platform capabilities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $13.80 $12.60

mln mln (1

Analyst)

Q2 EPS -$0.01

Q2 Net -$143,00

Income 0

Q2 Beat $478,000 -$87,000

Adjusted (1

EBITDA Analyst)

Q2 Gross 48.2%

Margin

Q2 -$258,00

Operatin 0

g Income

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the computer hardware peer group is "buy"

* Wall Street's median 12-month price target for TransAct Technologies Inc ( TACT ) is $5.00, about 22.8% above its August 5 closing price of $3.86

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says
Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says
Apr 17, 2024
April 17 (Reuters) - The U.S. Food and Drug Administration website showed that most doses of Eli Lilly's ( LLY ) diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarter of this year due to increased demand. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath) ...
Morgan Stanley, HSBC cutting Asia investment banking jobs on China deals slowdown
Morgan Stanley, HSBC cutting Asia investment banking jobs on China deals slowdown
Apr 17, 2024
HONG KONG, April 17 (Reuters) - Morgan Stanley ( MS ) and HSBC ( HSBC ) are cutting dozens of investment banking jobs in the Asia Pacific region this week, sources said, as they ramp up cost-cutting, with weaker dealmaking and sluggish markets in China and Hong Kong weighing on business prospects. Morgan Stanley ( MS ) is cutting at...
BRIEF-Vanda Pharmaceuticals Confirms Rejection Of Unsolicited Takeover Proposals From Future Pak
BRIEF-Vanda Pharmaceuticals Confirms Rejection Of Unsolicited Takeover Proposals From Future Pak
Apr 17, 2024
April 17 (Reuters) - Vanda Pharmaceuticals Inc ( VNDA ): * VANDA PHARMACEUTICALS CONFIRMS REJECTION OF UNSOLICITED TAKEOVER PROPOSALS FROM FUTURE PAK * VANDA PHARMACEUTICALS INC ( VNDA ) - BOARD DETERMINED UNSOLICITED TAKEOVER PROPOSALS SIGNIFICANTLY UNDERVALUE COMPANY Source text for Eikon: Further company coverage: ...
Boeing's safety culture in spotlight at U.S. Senate hearings
Boeing's safety culture in spotlight at U.S. Senate hearings
Apr 17, 2024
(Reuters) - Boeing's ( BA ) manufacturing practices, at the center of a full blown safety crisis following a Jan mid-air panel blowout, will come under scrutiny on Wednesday in two U.S. Senate hearings. Boeing ( BA ) has been grappling with a crisis that has undermined its reputation following the Jan. 5 mid-air panel blowout on a 737 MAX...
Copyright 2023-2026 - www.financetom.com All Rights Reserved